date:Dec 21, 2018
pilepsy. That approval was based on adequate and well-controlled clinical studies, which gives prescribers confidence in the drugs uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes.
In addition, pathways remain available for the FDA to consider whether there are circumstances in which certain cannabis-derived compounds might be permitted in a food or dietary supplement. Although such products a